Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2TerminatedINTERVENTIONAL

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

ClinicalTrials.gov · NCT00938314 · Registry updated: 2011-11-29

Condition / research focus: Stroke
Sponsor: Stem Cell Therapeutics Corp.
Countries with listed sites: Canada · India · United States
Registry dates and results: Start: 2009-08. Completion: 2010-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (drug) — also listed as: Ovidrel, Ovitrelle, Epogen, Eprex
human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (drug) — also listed as: Ovidrel, Ovitrelle, Epogen, Eprex
human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (drug) — also listed as: Ovidrel, Ovitrelle, Epogen, Eprex
Saline Placebo (drug) — also listed as: Sodium Chloride 0.9%

Where the study takes place — 23 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

University of California, Irvine Medical Center
Orange, California, United States
Site recruitment: Not reported
Foothills Medical Center , University of Calgary
Calgary, Alberta, Canada
Site recruitment: Not reported
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
Montreal Neurological Institute
Montreal, Quebec, Canada
Site recruitment: Not reported
Lalitha Super Specialty Hospitals Pvt.Ltd
Guntur, Andhra Pradesh, India
Site recruitment: Not reported
Care Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Krishna Institute of Medical Sciences
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
St.Theresa's General Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Apollo Hospitals
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Owaisi Hospital and Research Centre
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Mediciti Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Kamineni Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
DBR & SK Super Speciality Hospital
Tirupati, Andhra Pradesh, India
Site recruitment: Not reported
Latha Superspecialities Hospital
Vijayawada, Andhra Pradesh, India
Site recruitment: Not reported
Suraksha Neuro Centre
Vijayawada, Andhra Pradesh, India
Site recruitment: Not reported
M S Ramaiah Memorial Hospital
Bangalore, Karnataka, India
Site recruitment: Not reported
J.S.S Medical College & Hospital
Bangalore, Karnataka, India
Site recruitment: Not reported
Ananthapuri Hospitals and Research Institute
Thiruvananthapuram, Kerala, India
Site recruitment: Not reported
Max Super Speciality Hospital
New Delhi, National Capital Territory of Delhi, India
Site recruitment: Not reported
Christian Medical College and Hospital
Ludhiana, Punjab, India
Site recruitment: Not reported
Vijaya Health Center
Chennai, Tamil Nadu, India
Site recruitment: Not reported
Christian Medical College Hospital
Vellore, Tamil Nadu, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

MENOPUR® Versus FOLLISTIM®

ClinicalTrials.gov · NCT00802360 · Registry updated: 2011-11-02

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2008-12. Completion: 2010-01 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotropin (drug) — also listed as: highly purified menotropins, Menopur®, hMG
Progestrone vaginal insert (drug) — also listed as: progesterone, Endometrin®
follitropin beta (drug) — also listed as: Follistim Pen®, Follistim®
Progesterone in oil (drug)
Ganirelix (drug) — also listed as: ganirelix acetate, GnRH antagonist

Where the study takes place — 7 listed sites

Huntington Reproductive Center
Pasadena, California, United States
Site recruitment: Not reported
San Diego Fertility Center
San Diego, California, United States
Site recruitment: Not reported
Conceptions Reproductive Associates of Colorado
Littleton, Colorado, United States
Site recruitment: Not reported
Women's Medical Research Group, LLC
Clearwater, Florida, United States
Site recruitment: Not reported
The Advanced IVF Institute; Charles E. Miller, MD & Associates
Naperville, Illinois, United States
Site recruitment: Not reported
A Woman's Center for Reproductive Medicine
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
Center for Assisted Reproduction
Bedford, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

ClinicalTrials.gov · NCT00715364 · Registry updated: 2011-09-05

Condition / research focus: Stroke
Sponsor: Stem Cell Therapeutics Corp.
Countries with listed sites: United States
Registry dates and results: Start: 2009-08. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NTx™-265: rhCG, then rEPO (drug) — also listed as: Ovidrel, Epogen
Saline Placebo (drug) — also listed as: Sodium Chloride 0.9%

Where the study takes place — 2 listed sites

Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Site recruitment: Not reported
University of California, Irvine Medical Center
Orange, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles

ClinicalTrials.gov · NCT01414673 · Registry updated: 2011-08-11

Condition / research focus: Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-04. Completion: 2011-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (drug)

Where the study takes place — 1 listed sites

Uzbrussel
Brussels, Laarbeeklaan 101, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles

ClinicalTrials.gov · NCT01390207 · Registry updated: 2011-08-04

Condition / research focus: hCG
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-01. Completion: 2011-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

16mm triggering (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT00947713 · Registry updated: 2011-07-15

Condition / research focus: Endocrine System Diseases; Gonadal Disorders
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2009-08. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

low dose human chorionic gonadotropin (drug) — also listed as: human chorionic gonadotropin
Clomiphen citrate plus HMG (drug)

Where the study takes place — 1 listed sites

Royan institute, Reproductive Medicine Research Centre, ACECR
Tehran, Tehran Province, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination

ClinicalTrials.gov · NCT01232075 · Registry updated: 2011-07-12

Condition / research focus: Infertility
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2008-09. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Extended letrozole regimen (drug) — also listed as: letrozole 2.5mg/day from cycle day 1 to 9
Clomiphene citrate regimen (drug) — also listed as: Clomiphene citrate 100mg/day from cycle day 3 to 7

Where the study takes place — 2 listed sites

Ahmed Elgazzar hospital
Cairo, Egypt
Site recruitment: Not reported
Cairo university hospital
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve

ClinicalTrials.gov · NCT00646568 · Registry updated: 2011-06-23

Condition / research focus: Infertility
Sponsor: Hadassah Medical Organization
Countries with listed sites: Israel
Registry dates and results: Start: 2008-06. Completion: 2010-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

s.c. human chorionic gonadotropin (Pregnyl) (drug)

Where the study takes place — 1 listed sites

Hadassah Medical center
Jerusalem, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation

ClinicalTrials.gov · NCT00335569 · Registry updated: 2011-06-01

Condition / research focus: Infertility
Sponsor: IBSA Institut Biochimique SA
Countries with listed sites: Switzerland
Registry dates and results: Start: 2005-08. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG-IBSA (drug)

Where the study takes place — 4 listed sites

Department of Gynecology and Obstetrics Universitätfrauenklinik
Basel, Switzerland
Site recruitment: Not reported
4. Department of Gynecology and Obstetrics Frauenklinik, InselspitalEffingerstrasse 102
Bern, Switzerland
Site recruitment: Not reported
Department of Gynecology and ObstetricsUniversity Hospital
Geneva, Switzerland
Site recruitment: Not reported
3. Maternity CHUV - Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

ClinicalTrials.gov · NCT01205009 · Registry updated: 2011-03-02

Condition / research focus: Infertility
Sponsor: Hadassah Medical Organization
Countries with listed sites: Israel
Registry dates and results: Start: 2011-04. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Hadassah Medical Center
Jerusalem, Israel, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Proposed Research Protocol For Male Infertility

ClinicalTrials.gov · NCT01255397 · Registry updated: 2010-12-07

Condition / research focus: Male Infertility
Sponsor: HaEmek Medical Center, Israel
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Male Infertility Protocol (procedure)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

ClinicalTrials.gov · NCT01239706 · Registry updated: 2010-11-11

Condition / research focus: Traumatic Brain Injury
Sponsor: University of Calgary
Countries with listed sites: Canada
Registry dates and results: Start: 2010-11. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NTx 265 (drug) — also listed as: Eprex, Ortho Biotech, Ovidrel, Serono

Where the study takes place — 1 listed sites

Foothills Medical Center
Calgary, Alberta, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Low Dose hCG in the Late Follicular Phase

ClinicalTrials.gov · NCT00750100 · Registry updated: 2010-10-11

Condition / research focus: Infertility
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2007-09. Completion: 2008-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: Pregnyl, NV Organon, Oss, The Netherlands
recombinant gonadotropins (drug) — also listed as: Puregon, NV Organon, Oss, The Netherlands

Where the study takes place — 1 listed sites

UZ Brussel
Laarbeeklaan 101, Brussels Capital, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation

ClinicalTrials.gov · NCT00844311 · Registry updated: 2010-08-04

Condition / research focus: Infertility
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2009-02. Completion: 2010-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rFSH (drug)
human chorionic gonadotropin (drug)
human chorionic gonadotropin (drug)
human chorionic gonadotropin (drug)

Where the study takes place — 1 listed sites

The Fertility Clinic, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Synchronization of Follicle Wave Emergence and Ovarian Stimulation

ClinicalTrials.gov · NCT00439829 · Registry updated: 2010-05-25

Condition / research focus: Infertility
Sponsor: University of Saskatchewan
Countries with listed sites: Canada
Registry dates and results: Start: 2007-02. Completion: 2010-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal F (drug)
Luveris (drug)
Cetrotide (drug)
hCG (drug)

Where the study takes place — 2 listed sites

Genesis Fertility Centre
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium

ClinicalTrials.gov · NCT00976651 · Registry updated: 2010-03-25

Condition / research focus: Infertility
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-01. Completion: 2009-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human menopausal gonadotropin (drug)

Where the study takes place — 1 listed sites

UZ Brussel
Laarbeeklaan 101, Brussels Capital, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2UnknownINTERVENTIONAL

Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification

ClinicalTrials.gov · NCT00823121 · Registry updated: 2010-01-20

Condition / research focus: In Vitro Fertilization
Sponsor: Yazd Research & Clinical Center for Infertility
Countries with listed sites: Iran
Registry dates and results: Start: 2008-08. Completion: 2009-12 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

freezing embryos by vitrification (procedure) — also listed as: cryopreservation of embryos
fresh embryo transfers (procedure) — also listed as: embryo transfer using fresh embryos
buserelin (drug) — also listed as: suprefact
recombinant FSH (drug) — also listed as: Gonal F
human chorionic gonadotropin (pregnyl) (drug) — also listed as: pregnyl

Where the study takes place — 1 listed sites

: Research and clinical center for infertility
Yazd, Yazd Province, Iran
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)

ClinicalTrials.gov · NCT00954265 · Registry updated: 2009-12-24

Condition / research focus: Embryonic Development; Pregnancy; VEGF
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2005-08. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

10000 IU urinary HCG (drug)
250 mcg recombinant HCG (drug)

Where the study takes place — 1 listed sites

Centre for Reproductive Medicine, UZ Brussel
Brussels, Jette, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation

ClinicalTrials.gov · NCT01029470 · Registry updated: 2009-12-10

Condition / research focus: Infertility
Sponsor: Peking University Third Hospital
Countries with listed sites: China
Registry dates and results: Start: 2009-12. Completion: 2011-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Luveris (drug) — also listed as: Gonal-f, ovidrel

Where the study takes place — 1 listed sites

Peking University third Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization

ClinicalTrials.gov · NCT00985062 · Registry updated: 2009-09-28

Condition / research focus: Subfertility
Sponsor: Erasmus Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2004-10. Completion: 2006-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Mild Ovarian Stimulation Treatment (procedure)
Conventional Ovarian Stimulation Treatment (procedure)

Where the study takes place — 1 listed sites

Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2TerminatedINTERVENTIONAL

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

ClinicalTrials.gov · NCT00938314 · Registry updated: 2011-11-29

Condition / research focus: Stroke
Sponsor: Stem Cell Therapeutics Corp.
Countries with listed sites: Canada · India · United States
Registry dates and results: Start: 2009-08. Completion: 2010-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (drug) — also listed as: Ovidrel, Ovitrelle, Epogen, Eprex
human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (drug) — also listed as: Ovidrel, Ovitrelle, Epogen, Eprex
human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (drug) — also listed as: Ovidrel, Ovitrelle, Epogen, Eprex
Saline Placebo (drug) — also listed as: Sodium Chloride 0.9%

Where the study takes place — 23 listed sites

University of California, Irvine Medical Center
Orange, California, United States
Site recruitment: Not reported
Foothills Medical Center , University of Calgary
Calgary, Alberta, Canada
Site recruitment: Not reported
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
Montreal Neurological Institute
Montreal, Quebec, Canada
Site recruitment: Not reported
Lalitha Super Specialty Hospitals Pvt.Ltd
Guntur, Andhra Pradesh, India
Site recruitment: Not reported
Care Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Krishna Institute of Medical Sciences
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
St.Theresa's General Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Apollo Hospitals
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Owaisi Hospital and Research Centre
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Mediciti Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
Kamineni Hospital
Hyderabad, Andhra Pradesh, India
Site recruitment: Not reported
DBR & SK Super Speciality Hospital
Tirupati, Andhra Pradesh, India
Site recruitment: Not reported
Latha Superspecialities Hospital
Vijayawada, Andhra Pradesh, India
Site recruitment: Not reported
Suraksha Neuro Centre
Vijayawada, Andhra Pradesh, India
Site recruitment: Not reported
M S Ramaiah Memorial Hospital
Bangalore, Karnataka, India
Site recruitment: Not reported
J.S.S Medical College & Hospital
Bangalore, Karnataka, India
Site recruitment: Not reported
Ananthapuri Hospitals and Research Institute
Thiruvananthapuram, Kerala, India
Site recruitment: Not reported
Max Super Speciality Hospital
New Delhi, National Capital Territory of Delhi, India
Site recruitment: Not reported
Christian Medical College and Hospital
Ludhiana, Punjab, India
Site recruitment: Not reported
Vijaya Health Center
Chennai, Tamil Nadu, India
Site recruitment: Not reported
Christian Medical College Hospital
Vellore, Tamil Nadu, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

MENOPUR® Versus FOLLISTIM®

ClinicalTrials.gov · NCT00802360 · Registry updated: 2011-11-02

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2008-12. Completion: 2010-01 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotropin (drug) — also listed as: highly purified menotropins, Menopur®, hMG
Progestrone vaginal insert (drug) — also listed as: progesterone, Endometrin®
follitropin beta (drug) — also listed as: Follistim Pen®, Follistim®
Progesterone in oil (drug)
Ganirelix (drug) — also listed as: ganirelix acetate, GnRH antagonist

Where the study takes place — 7 listed sites

Huntington Reproductive Center
Pasadena, California, United States
Site recruitment: Not reported
San Diego Fertility Center
San Diego, California, United States
Site recruitment: Not reported
Conceptions Reproductive Associates of Colorado
Littleton, Colorado, United States
Site recruitment: Not reported
Women's Medical Research Group, LLC
Clearwater, Florida, United States
Site recruitment: Not reported
The Advanced IVF Institute; Charles E. Miller, MD & Associates
Naperville, Illinois, United States
Site recruitment: Not reported
A Woman's Center for Reproductive Medicine
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
Center for Assisted Reproduction
Bedford, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

ClinicalTrials.gov · NCT00715364 · Registry updated: 2011-09-05

Condition / research focus: Stroke
Sponsor: Stem Cell Therapeutics Corp.
Countries with listed sites: United States
Registry dates and results: Start: 2009-08. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NTx™-265: rhCG, then rEPO (drug) — also listed as: Ovidrel, Epogen
Saline Placebo (drug) — also listed as: Sodium Chloride 0.9%

Where the study takes place — 2 listed sites

Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Site recruitment: Not reported
University of California, Irvine Medical Center
Orange, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles

ClinicalTrials.gov · NCT01414673 · Registry updated: 2011-08-11

Condition / research focus: Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-04. Completion: 2011-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (drug)

Where the study takes place — 1 listed sites

Uzbrussel
Brussels, Laarbeeklaan 101, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles

ClinicalTrials.gov · NCT01390207 · Registry updated: 2011-08-04

Condition / research focus: hCG
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-01. Completion: 2011-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

16mm triggering (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT00947713 · Registry updated: 2011-07-15

Condition / research focus: Endocrine System Diseases; Gonadal Disorders
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2009-08. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

low dose human chorionic gonadotropin (drug) — also listed as: human chorionic gonadotropin
Clomiphen citrate plus HMG (drug)

Where the study takes place — 1 listed sites

Royan institute, Reproductive Medicine Research Centre, ACECR
Tehran, Tehran Province, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination

ClinicalTrials.gov · NCT01232075 · Registry updated: 2011-07-12

Condition / research focus: Infertility
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2008-09. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Extended letrozole regimen (drug) — also listed as: letrozole 2.5mg/day from cycle day 1 to 9
Clomiphene citrate regimen (drug) — also listed as: Clomiphene citrate 100mg/day from cycle day 3 to 7

Where the study takes place — 2 listed sites

Ahmed Elgazzar hospital
Cairo, Egypt
Site recruitment: Not reported
Cairo university hospital
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve

ClinicalTrials.gov · NCT00646568 · Registry updated: 2011-06-23

Condition / research focus: Infertility
Sponsor: Hadassah Medical Organization
Countries with listed sites: Israel
Registry dates and results: Start: 2008-06. Completion: 2010-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

s.c. human chorionic gonadotropin (Pregnyl) (drug)

Where the study takes place — 1 listed sites

Hadassah Medical center
Jerusalem, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation

ClinicalTrials.gov · NCT00335569 · Registry updated: 2011-06-01

Condition / research focus: Infertility
Sponsor: IBSA Institut Biochimique SA
Countries with listed sites: Switzerland
Registry dates and results: Start: 2005-08. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG-IBSA (drug)

Where the study takes place — 4 listed sites

Department of Gynecology and Obstetrics Universitätfrauenklinik
Basel, Switzerland
Site recruitment: Not reported
4. Department of Gynecology and Obstetrics Frauenklinik, InselspitalEffingerstrasse 102
Bern, Switzerland
Site recruitment: Not reported
Department of Gynecology and ObstetricsUniversity Hospital
Geneva, Switzerland
Site recruitment: Not reported
3. Maternity CHUV - Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

ClinicalTrials.gov · NCT01205009 · Registry updated: 2011-03-02

Condition / research focus: Infertility
Sponsor: Hadassah Medical Organization
Countries with listed sites: Israel
Registry dates and results: Start: 2011-04. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Hadassah Medical Center
Jerusalem, Israel, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Proposed Research Protocol For Male Infertility

ClinicalTrials.gov · NCT01255397 · Registry updated: 2010-12-07

Condition / research focus: Male Infertility
Sponsor: HaEmek Medical Center, Israel
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Male Infertility Protocol (procedure)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

ClinicalTrials.gov · NCT01239706 · Registry updated: 2010-11-11

Condition / research focus: Traumatic Brain Injury
Sponsor: University of Calgary
Countries with listed sites: Canada
Registry dates and results: Start: 2010-11. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NTx 265 (drug) — also listed as: Eprex, Ortho Biotech, Ovidrel, Serono

Where the study takes place — 1 listed sites

Foothills Medical Center
Calgary, Alberta, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Low Dose hCG in the Late Follicular Phase

ClinicalTrials.gov · NCT00750100 · Registry updated: 2010-10-11

Condition / research focus: Infertility
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2007-09. Completion: 2008-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: Pregnyl, NV Organon, Oss, The Netherlands
recombinant gonadotropins (drug) — also listed as: Puregon, NV Organon, Oss, The Netherlands

Where the study takes place — 1 listed sites

UZ Brussel
Laarbeeklaan 101, Brussels Capital, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation

ClinicalTrials.gov · NCT00844311 · Registry updated: 2010-08-04

Condition / research focus: Infertility
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2009-02. Completion: 2010-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rFSH (drug)
human chorionic gonadotropin (drug)
human chorionic gonadotropin (drug)
human chorionic gonadotropin (drug)

Where the study takes place — 1 listed sites

The Fertility Clinic, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Synchronization of Follicle Wave Emergence and Ovarian Stimulation

ClinicalTrials.gov · NCT00439829 · Registry updated: 2010-05-25

Condition / research focus: Infertility
Sponsor: University of Saskatchewan
Countries with listed sites: Canada
Registry dates and results: Start: 2007-02. Completion: 2010-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal F (drug)
Luveris (drug)
Cetrotide (drug)
hCG (drug)

Where the study takes place — 2 listed sites

Genesis Fertility Centre
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium

ClinicalTrials.gov · NCT00976651 · Registry updated: 2010-03-25

Condition / research focus: Infertility
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-01. Completion: 2009-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human menopausal gonadotropin (drug)

Where the study takes place — 1 listed sites

UZ Brussel
Laarbeeklaan 101, Brussels Capital, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2UnknownINTERVENTIONAL

Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification

ClinicalTrials.gov · NCT00823121 · Registry updated: 2010-01-20

Condition / research focus: In Vitro Fertilization
Sponsor: Yazd Research & Clinical Center for Infertility
Countries with listed sites: Iran
Registry dates and results: Start: 2008-08. Completion: 2009-12 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

freezing embryos by vitrification (procedure) — also listed as: cryopreservation of embryos
fresh embryo transfers (procedure) — also listed as: embryo transfer using fresh embryos
buserelin (drug) — also listed as: suprefact
recombinant FSH (drug) — also listed as: Gonal F
human chorionic gonadotropin (pregnyl) (drug) — also listed as: pregnyl

Where the study takes place — 1 listed sites

: Research and clinical center for infertility
Yazd, Yazd Province, Iran
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)

ClinicalTrials.gov · NCT00954265 · Registry updated: 2009-12-24

Condition / research focus: Embryonic Development; Pregnancy; VEGF
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2005-08. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

10000 IU urinary HCG (drug)
250 mcg recombinant HCG (drug)

Where the study takes place — 1 listed sites

Centre for Reproductive Medicine, UZ Brussel
Brussels, Jette, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation

ClinicalTrials.gov · NCT01029470 · Registry updated: 2009-12-10

Condition / research focus: Infertility
Sponsor: Peking University Third Hospital
Countries with listed sites: China
Registry dates and results: Start: 2009-12. Completion: 2011-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Luveris (drug) — also listed as: Gonal-f, ovidrel

Where the study takes place — 1 listed sites

Peking University third Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization

ClinicalTrials.gov · NCT00985062 · Registry updated: 2009-09-28

Condition / research focus: Subfertility
Sponsor: Erasmus Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2004-10. Completion: 2006-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Mild Ovarian Stimulation Treatment (procedure)
Conventional Ovarian Stimulation Treatment (procedure)

Where the study takes place — 1 listed sites

Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →